<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4845429</article-id><article-id pub-id-type="publisher-id">82</article-id><article-id pub-id-type="doi">10.1186/s12969-016-0082-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Therapeutic advances in the treatment of vasculitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Eleftheriou</surname><given-names>Despina</given-names></name><address><phone>004420 79052182</phone><fax>004420 7905 2882</fax><email>d.eleftheriou@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Brogan</surname><given-names>Paul A.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>ARUK centre for Paediatric and Adolescent Rheumatology, Institute of Child Health and Great Ormond St Hospital NHS Foundation Trust, 30 Guilford Street, London, WC1N 1EH UK </aff><aff id="Aff2"><label/>Department of Paediatric Rheumatology, Institute of Child Health and Great Ormond St Hospital NHS Foundation Trust, 30 Guilford Street, London, WC1 E1N UK </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>14</volume><elocation-id>26</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>4</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#169; Eleftheriou and Brogan. 2016</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p>Considerable therapeutic advances for the treatment of vasculitis of the young have been made in the past 10&#160;years, including the development of outcome measures that facilitate clinical trial design. Notably, these include: a recognition that some patients with Kawasaki Disease require corticosteroids as primary treatment combined with IVIG; implementation of rare disease trial design for polyarteritis nodosa to deliver the first randomised controlled trial for children; first clinical trials involving children for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis; and identification of monogenic forms of vasculitis that provide an understanding of pathogenesis, thus facilitating more targeted treatment. Robust randomised controlled trials for Henoch Sch&#246;nlein Purpura nephritis and Takayasu arteritis are needed; there is also an over-arching need for trials examining new agents that facilitate corticosteroid sparing, of particular importance in the paediatric population since glucocorticoid toxicity is a major concern.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/http://dx.doi.org/10.13039/501100000341</institution-id><institution>Arthritis Research UK</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Primary systemic vasculitides of the young are relatively rare diseases, but are associated with significant morbidity and mortality, particularly if there is diagnostic delay [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. There have been a number of notable advances recently in the field of paediatric vasculitis research, including the development of classification criteria; and tools to assess disease outcome for use in clinical trials and other research involving children with vasculitis [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Treatment regimens continue to improve, with the use of different immunosuppressive medications and newer therapeutic approaches such as biologic agents [<xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. With the exception of Kawasaki Disease, most of current treatment approaches for paediatric vasculitides are based on evidence from small case series, anecdotal observations, or adult studies [<xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. Therefore, treatment differs substantially throughout Europe; and even within a single country, experience and practices vary considerably. Given that vasculitides are rare, conducting large randomised controlled trials using traditional clinical trial design is usually not feasible. There is, however, a need for a standardized approach to the management of these rare paediatric rheumatic diseases [<xref ref-type="bibr" rid="CR8">8</xref>]. The SHARE (Single-Hub Access for Pediatric Rheumatology in Europe [<xref ref-type="bibr" rid="CR8">8</xref>]) project has been set up to address this unmet need, and one of the main aims is to provide recommendations for the management of paediatric rheumatological diseases in European countries. Within this context the SHARE vasculitis working group have recently provided consensus and (where possible) evidence-based statements to optimize and harmonize management of vasculitis (manuscript in preparation). A detailed description of this as yet unpublished guidance is beyond the scope of this review. It is also currently unclear how the impact of the SHARE guidance will be assessed for all the vasculitides; comparative effectiveness research methodologies may be required within the context of national or international patient registries. Indeed this approach is already underway for Kawasaki disease (KD), in the context of a British Paediatric Surveillance Unit study specifically examining the impact of new clinical guidelines for KD in the UK.</p><p>This review summarises therapeutic advances in current management strategies for systemic vasculitides, and describes important unmet needs. At the time of writing this review, the SHARE guidelines are not yet published; however, we have aligned the descriptions of vasculitis treatment with the SHARE recommendations, which the reader should refer to (when these become available) for more detailed guidance.</p></sec><sec id="Sec2"><title>HSP IgA vasculitis (Henoch&#8211;Sch&#246;nlein purpura)</title><p>IgA vasculitis is the new term for Henoch-Sch&#246;nlein purpura (HSP), and is the commonest systemic vasculitis in childhood [<xref ref-type="bibr" rid="CR9">9</xref>]. For the purposes of this review, however, we will use the term HSP since that is the term used in the paediatric classification criteria [<xref ref-type="bibr" rid="CR4">4</xref>], and the one most paediatricians are familiar with. It is defined in the latest Chapel Hill nomenclature (2012) as: vasculitis with IgA1-dominant immune deposits affecting small vessels (predominantly capillaries, venules, or arterioles); often involving skin, gastrointestinal tract and frequently causes arthritis; and associated with glomerulonephritis which is indistinguishable from IgA nephropathy [<xref ref-type="bibr" rid="CR10">10</xref>]. Classification criteria (Ankara 2008) are: palpable purpura in a predominantly lower limb distribution with at least 1 of 4 of: diffuse abdominal pain; any biopsy showing IgA deposition (mandatory criterion if rash is atypical); arthritis and/or arthralgia; haematuria and/or proteinuria [<xref ref-type="bibr" rid="CR4">4</xref>]. HSP has a variable and often relapsing course without specific laboratory findings, with a third of children having symptoms up to two weeks; another third up to 1&#160;month; and recurrence of symptoms within 4&#160;months of resolution in the remaining third [<xref ref-type="bibr" rid="CR11">11</xref>]. Henoch&#8211;Sch&#246;nlein nephritis (HSN) accounts for 1.6&#8211;3&#160;% of all childhood cases of end-stage renal failure (ESRF) in the UK [<xref ref-type="bibr" rid="CR12">12</xref>]. Generally speaking, HSP is a more severe illness in adults than in children [<xref ref-type="bibr" rid="CR13">13</xref>].</p><sec id="Sec3"><title>Therapeutic advances</title><p>There is a very poor evidence base to guide the management of HSP, particularly for those with the severe forms of HSP nephritis (HSPN), and thus very few true therapeutic advances. Early morbidity in the disease is due to GI involvement; late morbidity and the most important overall determinant of poor outcome is renal involvement [<xref ref-type="bibr" rid="CR11">11</xref>]. In children the management of HSP is mainly conservative because the extra renal manifestations are usually self-limited [<xref ref-type="bibr" rid="CR14">14</xref>]. Arthritis responds well to non-steroidal anti-inflammatory drugs (NSAIDs) [<xref ref-type="bibr" rid="CR14">14</xref>]. Severe skin lesions and gastrointestinal involvement could require a short course of an oral corticosteroid [<xref ref-type="bibr" rid="CR14">14</xref>]. Controlled studies have shown that corticosteroids do not prevent renal disease [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Despite that, patients with severe renal involvement usually do require corticosteroids combined with other immunosuppressive agents, and sometimes anti-proteinuric and antihypertensive agents [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec4"><title>Summary of the SHARE guidelines for HSP</title><p>The SHARE initiative represents an important major therapeutic contribution since it provides consensus guidance for the management of HSP and HSPN, amongst other vasculitides [<xref ref-type="bibr" rid="CR8">8</xref>]. In anticipation that these will be published imminently, a brief overview of the SHARE management algorithm for HSPN is as follows. Children with microscopic haematuria without renal dysfunction or proteinuria, and those with non-persistent mild-moderate proteinuria usually do not require any specific therapeutic intervention other than a &#8220;watchful waiting approach&#8221; since the prognosis is excellent. Those with more severe proteinuria and/or impaired glomerular filtration, and those with persistent proteinuria should be reviewed by a paediatric nephrologist, and a renal biopsy is usually recommended. Treatment thereafter includes first line therapy with corticosteroids: oral for all; and initially intravenous pulsed methylprednisolone for those with more severe renal involvement. For the severest cases, intravenous cyclophosphamide is usually required (sometimes with plasma exchange: seek expert advice) as additional first line treatment combined with corticosteroids. Immunosuppressants including azathioprine, mycophenolate mofetil (MMF), or intravenous cyclophosphamide may be considered as second-line agents for those with moderate HSPN. Whilst awaiting publication of the SHARE guidelines, for a comprehensive review of the treatment of HSPN, the reader is referred to [<xref ref-type="bibr" rid="CR17">17</xref>]. It must be emphasised, however, that in the absence of robust data for evidence supporting the treatment of nephritis, even in view of the much anticipated SHARE guidance, a randomised controlled trial for the treatment of HSPN is urgently needed.</p></sec></sec><sec id="Sec5"><title>ANCA associated vasculitis (AAV)</title><p>Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA; previously referred to as Wegener&#8217;s granulomatosis), microscopic polyangiitis (MPA), eosinophilic granulomatous polyangiitis (EGPA; previously referred to as Churg-Strauss syndrome), and the so-called renal-limited vasculitis [<xref ref-type="bibr" rid="CR13">13</xref>]. From a clinical perspective it may be useful to think of GPA as having two forms: a predominantly granulomatous form with mainly localised disease with chronic course; and a florid, acute small vessel vasculitic form characterised by severe pulmonary haemorrhage and/or rapidly progressive vasculitis, or other severe vasculitic manifestation [<xref ref-type="bibr" rid="CR13">13</xref>]. These two broad presentations may co-exist or present sequentially in individual paediatric and adult patients [<xref ref-type="bibr" rid="CR13">13</xref>].</p><sec id="Sec6"><title>Therapeutic advances</title><p>Renal morbidity and mortality is a major concern in the AAV, hence therapy aimed at preservation of renal function is a recurring theme for the treatment of AAV in both adults and children [<xref ref-type="bibr" rid="CR18">18</xref>]. Treatment for paediatric AAV is broadly similar to the approach in adults based on evidence derived from a number of clinical trials conducted by the European Vasculitis Study group (EUVAS) [<xref ref-type="bibr" rid="CR19">19</xref>]. The EUVAS group was developed to conduct interventional clinical trials aimed at optimizing treatments and outcomes for vasculitis patients [<xref ref-type="bibr" rid="CR19">19</xref>]. A total of 12 clinical trials involving over 1300 patients have been conducted that have defined the standard of care and permitted consensus treatment recommendations [<xref ref-type="bibr" rid="CR19">19</xref>]. Particular areas of focus were: the reduction in cyclophosphamide exposure; efficacy of plasma exchange in reducing renal morbidity; remission maintenance strategies; and establishing the efficacy of newer therapies [<xref ref-type="bibr" rid="CR19">19</xref>]. Notably, two of the clinical trials have involved children with AAV. These clinical trials, and how they have informed current practice for both adults and children with AAV are summarised below.</p><p>The CYCAZAREM trial (CYClophosphamide or AZAthioprine for REMission) recruited 144 new adult patients with AAV and compared a 3&#8211;6-month cyclophosphamide course, stopping when remission was achieved, to a standard 12-month course of cyclophosphamide. Both groups were then switched to azathioprine as maintenance therapy [<xref ref-type="bibr" rid="CR20">20</xref>]. No differences in remission or relapse rates were observed [<xref ref-type="bibr" rid="CR20">20</xref>]. The validation of sequential cyclophosphamide induction followed by azathioprine maintenance has subsequently served as the basis for later trials [<xref ref-type="bibr" rid="CR20">20</xref>]. Pulsed IV cyclophosphamide (CYCLOPS, CYCLophosphamide Oral versus PulSed) was then shown to be as effective as daily oral cyclophosphamide, with a 50&#160;% reduction in cumulative cyclophosphamide dose, and fewer adverse events [<xref ref-type="bibr" rid="CR21">21</xref>]. Based on these studies, current induction of remission therapy in adults and children with AAV includes corticosteroids and cyclophosphamide (usually 6&#8211;10 intravenous doses at 500&#8211;1000&#160;mg/m2 [maximum 1.2&#160;g] per dose, given every 3&#8211;4 weeks) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Intravenous pulsed cyclophosphamide is increasingly favoured over oral continuous cyclophosphamide in adults and children, because the reduced cumulative dose, and less neutropenic sepsis in adult patients, albeit without good prospective paediatric evidence [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p>In addition, B-cell depletion with rituximab has been explored as an alternative to cyclophosphamide for remission induction for AAV [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Efficacy of this treatment approach for severe renal disease in combination with two IV cyclophosphamide doses was evaluated in the RITUXVAS trial [<xref ref-type="bibr" rid="CR23">23</xref>]. This regimen had no benefit over a standard IV cyclophosphamide regimen in terms of efficacy or adverse event rate; but demonstrated that rituximab could provide clinically important cyclophosphamide sparing [<xref ref-type="bibr" rid="CR23">23</xref>]. Another US multicentre, randomized trial compared rituximab with cyclophosphamide for remission induction, and showed that rituximab was not inferior to daily oral cyclophosphamide for induction of remission in severe ANCA-associated vasculitis; and rituximab may be superior in patients with relapsing disease [<xref ref-type="bibr" rid="CR22">22</xref>]. These studies led to licensing of rituximab for remission induction of AAV in adults in the USA and Europe. Whether low-dose cyclophosphamide still has a role in induction therapies alongside rituximab remains uncertain. Notably, an ongoing international multicentre study is exploring the efficacy and safety of Rituximab in children with new onset, or relapsing AAV (the PEPRS study; NCT01750697). Whilst we are encouraged that industry are supporting and undertaking paediatric studies of new therapeutic agents in rare diseases such as AAV, we appreciate that studies of &#8220;older&#8221; drugs, or studies of combination drug therapy in the paediatric population may not be feasible (due to lack of industry support), even if desirable for some diseases.</p><p>Two further EUVAS trials evaluated whether cyclophosphamide could be replaced as an induction agent, either with methotrexate or MMF. The NORAM trial (Non-Renal Alternative treatment with Methotrexate) demonstrated that remission rates for non-severe GPA/MPA were similar at 6&#160;months between an oral methotrexate and an oral cyclophosphamide regimen; but that late relapse was more common after methotrexate [<xref ref-type="bibr" rid="CR24">24</xref>]. MMF also proved not inferior to an IV cyclophosphamide regimen at 6&#160;months in the MYCophenolate mofetil versus CYClophosphamide; MYCYC), trial but with a higher relapse rate in the MMF group. The higher relapse rate was confined to the PR3-ANCA-positive subgroup, and no differences in remission or relapse rates were seen in the MPO-ANCA patient subgroup [<xref ref-type="bibr" rid="CR25">25</xref>]. Importantly, for the first time, children were included in the MYCYC trial [<xref ref-type="bibr" rid="CR25">25</xref>]. Many differences exist in physiology, pathology, pharmacokinetics, and pharmacodynamics between children and adults. Inclusion of paediatric patients in large adult RCTs, therefore, by no means eliminates the need for separate paediatric studies, but this approach at least allows us to obtain some robust paediatric data rather than just directly extrapolating from purely adult studies.</p><p>Regarding maintenance regimens, the EUVAS group found MMF not to be superior to azathioprine for relapse prevention of AAV after cyclophosphamide induction in the IMPROVE trial [<xref ref-type="bibr" rid="CR26">26</xref>]. MMF is therefore not recommended as a routine remission maintenance agent, but can be used when azathioprine or methotrexate have failed to maintain remission in adults and children with AAV.</p><p>Rituximab was also considered to have role in relapse prevention, and repeat-dose rituximab was shown to be associated with fewer relapses than azathioprine, following cyclophosphamide induction in the French MAINRITSAN trial [<xref ref-type="bibr" rid="CR27">27</xref>]. An ongoing study led by both EUVAS and the Vasculitis Clinical Research Consortium (VCRC) is exploring the role of rituximab in treatment of relapsing disease in the RITAZAREM trial (NCT01697267).</p><p>Other biologic agents that have been considered in AAV therapy are anti-tumour necrosis alpha agents, but these were largely abandoned after a negative result in relapse prevention in an etanercept study [<xref ref-type="bibr" rid="CR28">28</xref>]. The T-cell co-stimulation inhibitor CTLA4-Ig (abatacept) is currently being studied in a randomized trial for treatment of non-severe, relapsing GPA (ABROGATE; NCT02108860). The ALEVIATE trial (NCT01405807), a small dose-finding trial of compassionate use of alemtuzumab (a monoclonal antibody against CD-52, found on mature lymphocytes), is ongoing. For EGPA, a single-centre, phase 2, uncontrolled study demonstrated that mepolizumab (a monoclonal antibody against IL-5) allowed glucocorticoid sparing over the course of the disease in most patients, with no relapses during the active 9-month treatment phase [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>Lastly, the PEXIVAS trial is comparing four different therapeutic combinations in a factorial design examining a reduced oral glucocorticoid regimen with a standard-dose regimen; with or without plasma exchange for adults with AAV and renal involvement (NCT00987389). Small case series have also indicated that plasma exchange reduces renal morbidity in children with AAV [<xref ref-type="bibr" rid="CR30">30</xref>]; but there are no ongoing or planned trials of therapeutic plasma exchange in children with AAV.</p></sec></sec><sec id="Sec7"><title>Kawasaki disease (KD)</title><p>Kawasaki disease (KD) is a self-limiting vasculitic syndrome that predominantly affects medium and small-sized arteries [<xref ref-type="bibr" rid="CR31">31</xref>]. KD has a worldwide distribution with a male preponderance, an ethnic bias towards oriental children, some seasonality, and occasional epidemics [<xref ref-type="bibr" rid="CR31">31</xref>]. The principal clinical features of Kawasaki disease are: (i) Fever persisting for &#8805;5&#160;days; (ii) Peripheral extremity changes (reddening of the palms and soles, indurative oedema and subsequent desquamation); (iii) Polymorphous exanthema; (iv) bilateral conjunctival injection/congestion; (v) lips and oral cavity changes (reddening/cracking of lips, strawberry tongue, oral and pharyngeal injection); (vi) acute non-purulent cervical lymphadenopathy [<xref ref-type="bibr" rid="CR32">32</xref>]. For the diagnosis of Kawasaki disease to be formally established five of the above six clinical features should be present [<xref ref-type="bibr" rid="CR32">32</xref>]. Children with fewer than five of the six principal features can be diagnosed with Kawasaki disease when coronary aneurysm or dilatation is recognized by two-dimensional echocardiography or coronary angiography [<xref ref-type="bibr" rid="CR32">32</xref>].</p><sec id="Sec8"><title>Therapeutic advances</title><p>Early recognition and treatment of KD with aspirin and intravenous immunoglobulin (IVIG) has been shown unequivocally by randomised controlled trials and meta-analysis to reduce the occurrence of CAA [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Currently, aspirin at a dose of 30&#8211;50&#160;mg/kg/day is recommended during the acute phase of the illness, as this may be better tolerated than higher doses in terms of gastrointestinal and other side effects [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. The dose should be reduced to an anti-platelet does of 3&#8211;5&#160;mg/Kg once fever and inflammation have subsided [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Notably however, IVIG resistance has been reported in up to 20&#160;% of cases and these patients are at increased risk of developing CAA unless they receive additional treatment [<xref ref-type="bibr" rid="CR31">31</xref>]. Corticosteroids are effective treatment for other forms of vasculitis, but early retrospective analyses suggested that corticosteroids were associated with increased risk of CAA [<xref ref-type="bibr" rid="CR31">31</xref>]. However, this almost certainly reflected selection bias as the sickest patients received steroids. Importantly, clinical trials evaluating the use of corticosteroids plus IVIG have produced seemingly confusing results, exemplified by a USA study of high dose methyl prednisolone showing no reduction in CAA, and the recent Japanese RAISE study (using a lower dose but longer duration of prednisolone) showing improved outcome [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Chen et al. recently reported a meta-analysis comparing the frequency of CAA in patients treated with IVIG plus corticosteroids or IVIG alone for the primary treatment of KD [<xref ref-type="bibr" rid="CR37">37</xref>]. They found that significantly fewer patients receiving IVIG&#8201;+&#8201;corticosteroids developed CAA than those receiving IVIG alone (7.6&#160;% versus 18.9&#160;%; OR: 0.3; 95&#160;% CI 0.20&#8211;0.46); there was no significant differences in frequency of severe adverse events between the steroid and non-steroid treatment groups [<xref ref-type="bibr" rid="CR37">37</xref>]. Chen&#8217;s meta-analysis provides convincing evidence that steroids combined with IVIG as initial treatment reduces overall risk of CAA in severe KD [<xref ref-type="bibr" rid="CR37">37</xref>]. However, neither the meta-analysis nor the RAISE study provides clear answers as to whether all children should be treated with corticosteroids, and what dose, duration and route of corticosteroids should be used [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p><p>With these caveats in mind, we recently proposed a pragmatic treatment approach for the use of corticosteroids based on the current data and recognise that some children would benefit from combination therapy of corticosteroid and IVIG as first line therapy for KD (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref> [<xref ref-type="bibr" rid="CR31">31</xref>].)<fig id="Fig1"><label>Fig. 1</label><caption><p>Recommended clinical guideline for the management of Kawasaki disease. Adapted from reference 31. *Treatment can be commenced before 5&#160;days of fever if sepsis excluded; treatment should also be given if the presentation is&#8201;&gt;&#8201;10&#160;days from fever onset if there are signs of persistent inflammation; **Kobayashi risk score &#8805;5 points X Refer to paediatric cardiologist; &#182; Other specific interventions such as PET scanning, addition of calcium channel blocker therapy, and coronary angioplasty at discretion of paediatric cardiologist. + Other immunomodulators may include ciclosporin. &#9829;For infants, Z score for internal coronary artery diameter &gt;7 based on Montreal normative <ext-link ext-link-type="uri" xlink:href="http://parameterz.blogspot.co.uk/2010/11/montreal-coronary-artery-z-scores.html">http://parameterz.blogspot.co.uk/2010/11/montreal-coronary-artery-z-scores.html</ext-link>
</p></caption><graphic xlink:href="12969_2016_82_Fig1_HTML" id="MO1"/></fig></p><p>Furthermore, there are emerging animal data and case reports suggesting a role for anti-TNF-&#945; for the treatment of KD [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. The most commonly used agent is infliximab, a chimeric murine/human IgG1 monoclonal antibody specifically binding TNF-&#945; [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. A recent multicentre study in the USA comparing IVIG and aspirin to IVIG/aspirin plus infliximab as initial therapy in an unselected group of KD patients has been completed and showed no reduction in CAA, although there was faster resolution of the acute phase response in the infliximab group [<xref ref-type="bibr" rid="CR7">7</xref>]. Although there was a trend towards reduced CAA injury, the study was underpowered to detect significant reduction in CAA [<xref ref-type="bibr" rid="CR7">7</xref>]. Thus, anti-TNF&#945; should be considered in patients with IVIG resistant KD, but not routinely as adjunctive and further study is required of its role in initial therapy primary therapy.</p><p>A number of other therapies are also currently explored in KD. An open label study is currently examining the efficacy of anakinra as first line therapy in KD (NCT02390596; KAWAKINRA). Another phase III multicentre, randomised, open-label, blinded-end point trial is currently evaluating the efficacy and safety of immunoglobulin plus ciclosporin in patients with severe KD in Japan (the KAICA Trial).</p></sec></sec><sec id="Sec9"><title>Polyarteritis nodosa (PAN)</title><p>Polyarteritis nodosa (PAN) is a primary systemic necrotizing vasculitis predominantly targeting medium-sized arteries [<xref ref-type="bibr" rid="CR1">1</xref>]. The classification criteria for childhood PAN are histologic evidence of necrotizing vasculitis in medium- or small-sized arteries or angiographic abnormalities (conventional angiography if magnetic resonance angiography is negative) as a mandatory criterion plus one of the following five: skin involvement, myalgia or muscle tenderness, hypertension, peripheral neuropathy, and renal involvement [<xref ref-type="bibr" rid="CR4">4</xref>]. In children, various systems are involved in PAN with the skin, the musculoskeletal system, the kidneys, and the gastrointestinal tract most prominently affected; and cardiac, neurologic, and respiratory manifestations occurring less frequently [<xref ref-type="bibr" rid="CR1">1</xref>].</p><sec id="Sec10"><title>Therapeutic advances</title><p>Current treatment of PAN in children is based on limited trial data in adults. There are a number of RCTs for treatment of PAN, all relating to adults [<xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>]. Conclusions based on RCTs in adults with PAN with important implications for children are: a) treatment of severe PAN requires corticosteroids combined with intravenous cyclophosphamide; b) despite therapy, mortality associated with PAN in adults remains high at 4&#8211;22&#160;%; treatment-related toxicity contributes to this; c) adverse events (disease and treatment-related) affect 54&#8211;100&#160;% patients; and d) avoidance of cyclophosphamide in children is desirable if alternatives exist since complications associated with cyclophosphamide include infertility and malignancy [<xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>]. In line with this, in the largest published cohort of paediatric PAN patients, cyclophosphamide was used in combination with steroids as first line therapy in 83&#160;% of the cases albeit with a number of significant adverse events such as neutropenia and sepsis noted [<xref ref-type="bibr" rid="CR1">1</xref>]. Based on the fact that MMF appears to be an alternative to cyclophosphamide for induction of remission in other systemic vasculitides and autoimmune diseases with low toxicity profile, the MYPAN study (Mycophenolate mofetil for childhood PAN) was set up to explore whether MMF is non-inferior to cyclophosphamide, and with comparable (or less) short medium term safety in children with PAN [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Given that a definitive trial analysed by frequentist statistical methods would require 513 patients per arm and would take well over 30&#160;years to recruit [<xref ref-type="bibr" rid="CR44">44</xref>], the MYPAN study adopts a Bayesian approach, first characterising expert prior opinion about the 6-month remission rate on CYC and the relative benefit of MMF as probability distributions before the trial begins, and then updating these distributions using Bayes theorem once data become available [<xref ref-type="bibr" rid="CR44">44</xref>]. Using this rare disease trial design we hope to deliver the first clinical trial in childhood PAN.</p><p>Use of biologic agents, including anti TNF-&#945;, and rituximab is also described for children with systemic PAN, particularly those not responding to standard therapy or because of concern regarding cumulative cyclophosphamide toxicity [<xref ref-type="bibr" rid="CR5">5</xref>]. These therapies have not been formally assessed in RCTs in either children or adults with PAN, however.</p></sec></sec><sec id="Sec11"><title>Takayasu arteritis</title><p>Takayasu arteritis (TA) is the only large vessel vasculitis (LVV) referred to in the current paediatric classification, affecting the aorta and its major branches [<xref ref-type="bibr" rid="CR45">45</xref>]. TA has a worldwide distribution, with a reported incidence of 1.2&#8211;2.6/million per year in Caucasians, and a 100-fold higher incidence in East Asians [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Although the disease rarely affects children, it does occur even in infants [<xref ref-type="bibr" rid="CR2">2</xref>]. The clinical diagnosis of TA is usually challenging [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. An initial florid inflammatory vasculitic phase is followed by a later fibrotic/stenotic phase of the illness [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. It is estimated that one-third of children present within this late fibrotic/stenotic phase of the disease [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. It is a misconception that this is in some way an &#8220;inactive&#8221;, or &#8220;burnt-out&#8221; stage of the disease, since progressive stenotic disease may be the consequence of persistent but low-level large vessel vasculitic disease activity, but without evidence of conventional laboratory markers of systemic inflammation such as elevated C reactive protein, or increased erythrocyte sedimentation rate [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Diagnostic delay in children is unfortunately common and almost certainly contributes to worse outcomes [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p>Although hypertension and/or its sequelae is the most common form of presentation in both children and adults, the overall clinical spectrum at presentation of children with TA may differ from that in adults [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. The most frequent presentation in children is with arterial hypertension (82&#160;%) followed by headaches (31&#160;%), fever (29&#160;%), dyspnoea (23&#160;%), and weight loss (22&#160;%) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Musculoskeletal symptoms affect approximately 14&#8211;65&#160;% of children with TA [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. In contrast, adults rarely report arthritis or arthralgia. Bruits (48&#160;%) and claudication (27&#160;%) are more commonly reported in adults with TA [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Ocular manifestations are also rare in children [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. A detailed overview of imaging in TA is beyond the scope of this review, and we refer the reader elsewhere for this [<xref ref-type="bibr" rid="CR2">2</xref>].</p><sec id="Sec12"><title>Therapeutic advances in TA</title><p>There have been no randomised controlled trials to guide treatment, and few evidence-based therapeutic advances. Biologic therapies are increasingly used in children, particularly anti-TNF&#945; [<xref ref-type="bibr" rid="CR5">5</xref>], and anecdotally are reported to be efficacious. A major therapeutic challenge, however, is that there remains significant diagnostic delay for TA in children. This leads to significant and sometimes irreversible damage in the pre-diagnostic phase of the illness. At the time of writing, a major clinical trial of tocilizumab (a monoclonal antibody against the interleukin 6 receptor) for the treatment of giant cell arteritis in adults is ongoing [<xref ref-type="bibr" rid="CR49">49</xref>], and hopefully will report later in 2016. It is debatable, however, what relevance this might have for children with TA.</p><p>SHARE guidelines for the treatment of TA in the paediatric population will be formally published soon. The general therapeutic approach is that of induction of remission (high dose corticosteroid combined with another immunosuppressant), followed by maintenance of remission therapy (lower dose corticosteroid combined with a maintenance immunosuppressive agent, usually methotrexate), or institution of second line therapy for failed induction [<xref ref-type="bibr" rid="CR2">2</xref>]. Corticosteroids are the mainstay of first-line treatment for TA [<xref ref-type="bibr" rid="CR2">2</xref>]. In addition, methotrexate, azathioprine, MMF, and cyclophosphamide have been used in children as first or second line agents [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Ozen, et al. described 6 children with TA, and treatment with steroid and cyclophosphamide induction followed by MTX was suggested as effective and safe for childhood TA [<xref ref-type="bibr" rid="CR50">50</xref>]. Anti-TNF therapy may be beneficial [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Promising results have also been reported with anti-IL6 therapy (tocilizumab) for adults with TA, and in some cases children [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Surgical intervention is frequently required to alleviate end-organ ischemia and hypertension resulting from vascular stenosis, although it is preferable to control the vasculitic process before performing revascularisation procedures or other vascular surgery, if possible, since outcomes are worse if these are undertaken when the disease is still active [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p>The 5&#160;year mortality rate of TA in children has been reported as high as 35&#160;%; we recently reported 27&#160;% mortality from TA in children [<xref ref-type="bibr" rid="CR2">2</xref>]. Prognosis is dependent upon the extent of arterial involvement and organ damage at presentation; age of patient at disease onset (children under 5 have poorer prognosis); and on the severity of hypertension [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. It is unlikely that a randomised controlled trial for TA in children will be undertaken in the foreseeable future; extrapolation from adult trials (such as the soon-to-be reported tocilizumab trial) will provide some evidence base, but with all the caveats around using data from adult trials to inform paediatric practice.</p></sec></sec><sec id="Sec13"><title>Monogenic vasculitides: DADA2; CANDLE; and SAVI</title><p>Three recently described monogenic autoinflammatory conditions with a major vasculitic component are worthy of description in brief, since they highlight the concept that understanding the molecular pathogenesis may lead to more targeted therapy [<xref ref-type="bibr" rid="CR54">54</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref>].</p><sec id="Sec14"><title>DADA2</title><p>Deficiency of adenosine deaminase type 2 (DADA2) is an autosomal recessive disease resembling polyarteritis nodosa, caused by homozygous or compound heterozygous mutations in the <italic>CECR1</italic> gene [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. The cardinal clinical features include livedo racemosa, neurological involvement including propensity to lacunar (small vessel) stroke, vasculitic peripheral neuropathy, digital ischaemia and cutaneous ulceration, systemic inflammation, and other end organ damage [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. There is an emerging view that anti TNF alpha is particularly efficacious for this form of monogenic vasculitis [<xref ref-type="bibr" rid="CR59">59</xref>]; this may be due to the fact that the extracellular enzyme ADA2 functions as an important regulator of immune development. Patients with DADA2 demonstrate skewed macrophage development towards the M1 pro-inflammatory phenotype as opposed to the M2 anti-inflammatory phenotype [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. M1 macrophages are known to produce TNF alpha, which could explain why this therapeutic approach seems particularly effective in DADA2 [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Allogeneic haematopoietic stem cell transplantation has been reported to be successful in a few patients [<xref ref-type="bibr" rid="CR60">60</xref>]; gene therapy may be an option for the future [<xref ref-type="bibr" rid="CR59">59</xref>].</p></sec><sec id="Sec15"><title>CANDLE and SAVI</title><p>CANDLE syndrome (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature) is a recessive disease caused by homozygous, compound heterozygous or digenic mutations in the proteasome pathway, and is classified as a proteasome-associated autoinflammatory syndrome (PRAAS) [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Mutations in PSMB8, PSMB4, PSMB9, PSMA3, and proteasome maturation protein (POMP) are described [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. In the early stages, the neutrophilic dermatosis may display the histological features of neutrophilic/leukocytoclastic vasculitis (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). CANDLE is associated with dysregulated type I interferon production, therefore targeting this pathway with Janus kinase (JAK) inhibitors may be a promising novel therapeutic approach [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Early clinical trials of baricitinib, an oral JAK1 and JAK2 inhibitor, are ongoing.</p><p>Stimulator of interferon genes (STING)-associated vasculitis of infancy (SAVI) arises from sporadic/dominant mutation in the <italic>TMEM173</italic> gene and presents early in life with a vasculitic rash affecting the cheeks, nose, and peripheries (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>) with chronic ulceration; and progressive interstitial pulmonary fibrosis and associated pulmonary hypertension [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Standard vasculitis therapies are ineffective. Cutaneous vasculitis and deteriorating lung function usually continue relentlessly throughout childhood, with development of pulmonary hypertension and lung fibrosis, often with fatal outcome [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. SAVI is considered part of the growing group of Mendelian disorders recognised as &#8220;interferonopathies&#8221; which include Aicardi&#8211;Gouti&#232;res syndrome (AGS), and the aforementioned CANDLE syndrome [<xref ref-type="bibr" rid="CR63">63</xref>]. Whilst there are virtually no published data currently available, anecdotal reports again suggest that early treatment targeting the interferon pathway (e.g. with JAK inhibitors) currently offers the best hope for survival.<fig id="Fig2"><label>Fig. 2</label><caption><p>High power view of skin biopsy taken from an 8&#160;week old infant with CANDLE syndrome caused by digenic mutation in PSMB4 and PSMB9. There is a florid leukocytoclastic cutaneous vasculitis with karyorrhectic debris. In most areas distinct vessels could not be identified due to the destructive vasculitic process</p></caption><graphic xlink:href="12969_2016_82_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Chronic scarring of the pinna in a 12-year old boy with SAVI</p></caption><graphic xlink:href="12969_2016_82_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec16"><title>Concluding remarks</title><p>Considerable therapeutic advances for the treatment of vasculitis of the young have been made in the past 10&#160;years, including the development of outcome measures that facilitate clinical trial design. Notably, these include: a recognition that some patients with KD require corticosteroids as primary treatment combined with IVIG; implementation of rare disease trial design for PAN to deliver the first randomised controlled trial for children; first clinical trials involving children for ANCA vasculitis (MYCYC and PEPRS); and identification of monogenic forms of vasculitis that provide an understanding of pathogenesis facilitating more targeted treatment [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR54">54</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref>]. Priorities for future research have been identified including a need for robust randomised controlled trials for HSPN; therapeutic trials for TA; and an over-arching need for trials examining new agents that facilitate corticosteroid sparing, of particular importance in the paediatric population since glucocorticoid toxicity is a major concern.</p></sec></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#8217; contribution</bold></p><p>Both authors read and approved the final manuscript.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eleftheriou</surname><given-names>D</given-names></name><name><surname>Dillon</surname><given-names>MJ</given-names></name><name><surname>Tullus</surname><given-names>K</given-names></name><name><surname>Marks</surname><given-names>SD</given-names></name><name><surname>Pilkington</surname><given-names>CA</given-names></name><name><surname>Roebuck</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years</article-title><source>Arthritis Rheum</source><year>2013</year><volume>65</volume><fpage>2476</fpage><lpage>2485</lpage><pub-id pub-id-type="doi">10.1002/art.38024</pub-id><?supplied-pmid 23754739?><pub-id pub-id-type="pmid">23754739</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eleftheriou</surname><given-names>D</given-names></name><name><surname>Varnier</surname><given-names>G</given-names></name><name><surname>Dolezalova</surname><given-names>P</given-names></name><name><surname>McMahon</surname><given-names>AM</given-names></name><name><surname>Al-Obaidi</surname><given-names>M</given-names></name><name><surname>Brogan</surname><given-names>PA</given-names></name></person-group><article-title>Takayasu arteritis in childhood: retrospective experience from a tertiary referral centre in the UK</article-title><source>Arthritis Res &amp; Ther</source><year>2015</year><volume>17</volume><fpage>545</fpage><pub-id pub-id-type="doi">10.1186/s13075-015-0545-1</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolezalova</surname><given-names>P</given-names></name><name><surname>Price-Kuehne</surname><given-names>FE</given-names></name><name><surname>Ozen</surname><given-names>S</given-names></name><name><surname>Benseler</surname><given-names>SM</given-names></name><name><surname>Cabral</surname><given-names>DA</given-names></name><name><surname>Anton</surname><given-names>J</given-names></name><etal/></person-group><article-title>Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>1628</fpage><lpage>1633</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202111</pub-id><?supplied-pmid 23100606?><pub-id pub-id-type="pmid">23100606</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozen</surname><given-names>S</given-names></name><name><surname>Pistorio</surname><given-names>A</given-names></name><name><surname>Iusan</surname><given-names>SM</given-names></name><name><surname>Bakkaloglu</surname><given-names>A</given-names></name><name><surname>Herlin</surname><given-names>T</given-names></name><name><surname>Brik</surname><given-names>R</given-names></name><etal/></person-group><article-title>EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>69</volume><fpage>798</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.116657</pub-id><?supplied-pmid 20413568?><pub-id pub-id-type="pmid">20413568</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eleftheriou</surname><given-names>D</given-names></name><name><surname>Melo</surname><given-names>M</given-names></name><name><surname>Marks</surname><given-names>SD</given-names></name><name><surname>Tullus</surname><given-names>K</given-names></name><name><surname>Sills</surname><given-names>J</given-names></name><name><surname>Cleary</surname><given-names>G</given-names></name><etal/></person-group><article-title>Biologic therapy in primary systemic vasculitis of the young</article-title><source>Rheum(Oxford)</source><year>2009</year><volume>48</volume><fpage>978</fpage><lpage>86</lpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Shinohara</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Tomomasa</surname><given-names>T</given-names></name><etal/></person-group><article-title>A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome</article-title><source>J Pediatr</source><year>2006</year><volume>149</volume><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2006.05.025</pub-id><?supplied-pmid 16939743?><pub-id pub-id-type="pmid">16939743</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremoulet</surname><given-names>AH</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Jaggi</surname><given-names>P</given-names></name><name><surname>Jimenez-Fernandez</surname><given-names>S</given-names></name><name><surname>Pancheri</surname><given-names>JM</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2014</year><volume>383</volume><fpage>1731</fpage><lpage>1738</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)62298-9</pub-id><?supplied-pmid 24572997?><pub-id pub-id-type="pmid">24572997</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wulffraat</surname><given-names>NM</given-names></name><name><surname>Vastert</surname><given-names>B</given-names></name></person-group><article-title>Time to share</article-title><source>Pediatric Rheumatology</source><year>2013</year><volume>11</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1186/1546-0096-11-5</pub-id><pub-id pub-id-type="pmid">23302539</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner-Medwin</surname><given-names>JM</given-names></name><name><surname>Dolezalova</surname><given-names>P</given-names></name><name><surname>Cummins</surname><given-names>C</given-names></name><name><surname>Southwood</surname><given-names>TR</given-names></name></person-group><article-title>Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>1197</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)11279-7</pub-id><?supplied-pmid 12401245?><pub-id pub-id-type="pmid">12401245</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennette</surname><given-names>JC</given-names></name><name><surname>Falk</surname><given-names>RJ</given-names></name><name><surname>Bacon</surname><given-names>PA</given-names></name><name><surname>Basu</surname><given-names>N</given-names></name><name><surname>Cid</surname><given-names>MC</given-names></name><name><surname>Ferrario</surname><given-names>F</given-names></name><etal/></person-group><article-title>Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides</article-title><source>Arthritis Rheum</source><year>2012</year><volume>2013</volume><issue>65</issue><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapani</surname><given-names>S</given-names></name><name><surname>Micheli</surname><given-names>A</given-names></name><name><surname>Grisolia</surname><given-names>F</given-names></name><name><surname>Resti</surname><given-names>M</given-names></name><name><surname>Chiappini</surname><given-names>E</given-names></name><name><surname>Falcini</surname><given-names>F</given-names></name><etal/></person-group><article-title>Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature</article-title><source>Semin Arthritis Rheum</source><year>2005</year><volume>35</volume><fpage>143</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2005.08.007</pub-id><?supplied-pmid 16325655?><pub-id pub-id-type="pmid">16325655</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Heijden</surname><given-names>BJ</given-names></name><name><surname>van Dijk</surname><given-names>PC</given-names></name><name><surname>Verrier-Jones</surname><given-names>K</given-names></name><name><surname>Jager</surname><given-names>KJ</given-names></name><name><surname>Briggs</surname><given-names>JD</given-names></name></person-group><article-title>Renal replacement therapy in children: data from 12 registries in Europe</article-title><source>Pediat Nephrol</source><year>2004</year><volume>19</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1007/s00467-003-1376-x</pub-id><?supplied-pmid 14685843?><pub-id pub-id-type="pmid">14685843</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eleftheriou</surname><given-names>D</given-names></name><name><surname>Batu</surname><given-names>ED</given-names></name><name><surname>Ozen</surname><given-names>S</given-names></name><name><surname>Brogan</surname><given-names>PA</given-names></name></person-group><article-title>Vasculitis in children</article-title><source>Nephrol Dial Transplant</source><year>2015</year><volume>30</volume><fpage>i94</fpage><lpage>i103</lpage><?supplied-pmid 25550447?><pub-id pub-id-type="pmid">25550447</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozen</surname><given-names>S</given-names></name></person-group><article-title>The spectrum of vasculitis in children</article-title><source>Best Pract Res Clin Rheumatol</source><year>2002</year><volume>16</volume><fpage>411</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/S1521-6942(02)90237-8</pub-id><?supplied-pmid 12387808?><pub-id pub-id-type="pmid">12387808</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chartapisak</surname><given-names>W</given-names></name><name><surname>Opastiraku</surname><given-names>S</given-names></name><name><surname>Willis</surname><given-names>NS</given-names></name><name><surname>Craig</surname><given-names>JC</given-names></name><name><surname>Hodson</surname><given-names>EM</given-names></name></person-group><article-title>Prevention and treatment of renal disease in Henoch-Schonlein purpura: a systematic review</article-title><source>Arch Dis Child</source><year>2009</year><volume>94</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1136/adc.2008.141820</pub-id><?supplied-pmid 18701559?><pub-id pub-id-type="pmid">18701559</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudley</surname><given-names>J</given-names></name><name><surname>SMITH</surname><given-names>G</given-names></name><name><surname>Llewelyn-Edwards</surname><given-names>A</given-names></name><name><surname>Bayliss</surname><given-names>K</given-names></name><name><surname>Pike</surname><given-names>K</given-names></name><name><surname>Tizard</surname><given-names>J</given-names></name></person-group><article-title>Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP)</article-title><source>Arch Dis Child</source><year>2013</year><volume>98</volume><fpage>756</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2013-303642</pub-id><?supplied-pmid 23845696?><pub-id pub-id-type="pmid">23845696</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaffanello</surname><given-names>M</given-names></name><name><surname>Fanos</surname><given-names>V</given-names></name></person-group><article-title>Treatment-based literature of Henoch&#8201;&#8722;&#8201;Schonlein purpura nephritis in childhood</article-title><source>Pediatr Nephrol</source><year>2009</year><volume>24</volume><fpage>1901</fpage><lpage>1911</lpage><pub-id pub-id-type="doi">10.1007/s00467-008-1066-9</pub-id><?supplied-pmid 19066976?><pub-id pub-id-type="pmid">19066976</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabral</surname><given-names>DA</given-names></name><name><surname>Uribe</surname><given-names>AG</given-names></name><name><surname>Benseler</surname><given-names>S</given-names></name><name><surname>O&#8217;Neil</surname><given-names>KM</given-names></name><name><surname>Hashkes</surname><given-names>PJ</given-names></name><name><surname>Higgins</surname><given-names>G</given-names></name><etal/></person-group><article-title>Classification, presentation, and initial treatment of Wegener&#8217;s granulomatosis in childhood</article-title><source>Arthritis &amp; Rheumatism</source><year>2009</year><volume>60</volume><fpage>3413</fpage><lpage>3424</lpage><pub-id pub-id-type="doi">10.1002/art.24876</pub-id><pub-id pub-id-type="pmid">19877069</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayne</surname><given-names>D</given-names></name><name><surname>Rasmussen</surname><given-names>N</given-names></name></person-group><article-title>Twenty-five years of European Union collaboration in ANCA-associated vasculitis research</article-title><source>Nephrol Dial Transplant</source><year>2015</year><volume>30</volume><fpage>i1</fpage><lpage>i7</lpage><?supplied-pmid 25805742?><pub-id pub-id-type="pmid">25805742</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayne</surname><given-names>D</given-names></name><name><surname>Rasmussen</surname><given-names>N</given-names></name><name><surname>Andrassy</surname><given-names>K</given-names></name><name><surname>Bacon</surname><given-names>P</given-names></name><name><surname>Tervaert</surname><given-names>JW</given-names></name><name><surname>Dadoniene</surname><given-names>J</given-names></name><etal/></person-group><article-title>A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020286</pub-id><?supplied-pmid 12840090?><pub-id pub-id-type="pmid">12840090</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>L</given-names></name><name><surname>Morgan</surname><given-names>MD</given-names></name><name><surname>Walsh</surname><given-names>M</given-names></name><name><surname>Hoglund</surname><given-names>P</given-names></name><name><surname>Westman</surname><given-names>K</given-names></name><name><surname>Flossmann</surname><given-names>O</given-names></name><etal/></person-group><article-title>Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up</article-title><source>Ann Rheum Dis</source><year>2012</year><volume>71</volume><fpage>955</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2011-200477</pub-id><?supplied-pmid 22128076?><pub-id pub-id-type="pmid">22128076</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>JH</given-names></name><name><surname>Merkel</surname><given-names>PA</given-names></name><name><surname>Spiera</surname><given-names>R</given-names></name><name><surname>Seo</surname><given-names>P</given-names></name><name><surname>Langford</surname><given-names>CA</given-names></name><name><surname>Hoffman</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Rituximab versus cyclophosphamide for ANCA-associated vasculitis</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0909905</pub-id><?supplied-pmid 20647199?><pub-id pub-id-type="pmid">20647199</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RB</given-names></name><name><surname>Cohen Tervaert</surname><given-names>JW</given-names></name><name><surname>Hauser</surname><given-names>T</given-names></name><name><surname>Luqmani</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>MD</given-names></name><name><surname>Peh</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0909169</pub-id><?supplied-pmid 20647198?><pub-id pub-id-type="pmid">20647198</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>K</given-names></name><name><surname>Rasmussen</surname><given-names>N</given-names></name><name><surname>Bacon</surname><given-names>PA</given-names></name><name><surname>Tervaert</surname><given-names>JW</given-names></name><name><surname>Feighery</surname><given-names>C</given-names></name><name><surname>Gregorini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>2461</fpage><lpage>2469</lpage><pub-id pub-id-type="doi">10.1002/art.21142</pub-id><?supplied-pmid 16052573?><pub-id pub-id-type="pmid">16052573</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Harper</surname><given-names>L</given-names></name><name><surname>Ballarin</surname><given-names>J</given-names></name><name><surname>Blockmans</surname><given-names>D</given-names></name><name><surname>Brogan</surname><given-names>P</given-names></name><name><surname>Bruchfeld</surname><given-names>A</given-names></name><etal/></person-group><article-title>A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis:MYCYC. On behalf of the European vasculitis study group</article-title><source>Presse Med</source><year>2013</year><volume>42</volume><fpage>678</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.lpm.2013.02.067</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiemstra</surname><given-names>TF</given-names></name><name><surname>Walsh</surname><given-names>M</given-names></name><name><surname>Mahr</surname><given-names>A</given-names></name><name><surname>Savage</surname><given-names>CO</given-names></name><name><surname>De</surname><given-names>GK</given-names></name><name><surname>Harper</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial</article-title><source>JAMA</source><year>2010</year><volume>304</volume><fpage>2381</fpage><lpage>2388</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.1658</pub-id><?supplied-pmid 21060104?><pub-id pub-id-type="pmid">21060104</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>LA</given-names></name><name><surname>Alvarado</surname><given-names>A</given-names></name><name><surname>Rovin</surname><given-names>B</given-names></name><name><surname>Guillevin</surname><given-names>L</given-names></name><name><surname>Pagnoux</surname><given-names>C</given-names></name><name><surname>Karras</surname><given-names>A</given-names></name></person-group><article-title>Rituximab or azathioprine maintenance in ANCA-associated vasculitis</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>385</fpage><pub-id pub-id-type="doi">10.1056/NEJMc1414728</pub-id><?supplied-pmid 25607434?><pub-id pub-id-type="pmid">25607434</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Wegener&#8217;s Granulomatosis Etanercept Trial (WGET) Research Group</collab></person-group><article-title>Etanercept plus standard therapy for Wegener&#8217;s granulomatosis</article-title><source>The N Engl J Med</source><year>2005</year><volume>352</volume><fpage>351</fpage><pub-id pub-id-type="doi">10.1056/NEJMoa041884</pub-id><pub-id pub-id-type="pmid">15673801</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ME</given-names></name><name><surname>Klion</surname><given-names>AD</given-names></name><name><surname>Roufosse</surname><given-names>FE</given-names></name><name><surname>Kahn</surname><given-names>JE</given-names></name><name><surname>Weller</surname><given-names>PF</given-names></name><name><surname>Simon</surname><given-names>HU</given-names></name><etal/></person-group><article-title>Treatment of patients with the hypereosinophilic syndrome with mepolizumab</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>1215</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa070812</pub-id><?supplied-pmid 18344568?><pub-id pub-id-type="pmid">18344568</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>E</given-names></name><name><surname>Dillon</surname><given-names>MJ</given-names></name><name><surname>Tullus</surname><given-names>K</given-names></name></person-group><article-title>Childhood vasculitis and plasma exchange</article-title><source>Eur J Pediatr</source><year>2007</year><volume>166</volume><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1007/s00431-006-0212-2</pub-id><?supplied-pmid 16915376?><pub-id pub-id-type="pmid">16915376</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eleftheriou</surname><given-names>D</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Shingadia</surname><given-names>D</given-names></name><name><surname>Tulloh</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>NJ</given-names></name><name><surname>Brogan</surname><given-names>PA</given-names></name></person-group><article-title>Management of Kawasaki disease</article-title><source>Arch Dis Child</source><year>2014</year><volume>99</volume><fpage>74</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2012-302841</pub-id><?supplied-pmid 24162006?><pub-id pub-id-type="pmid">24162006</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Gerber</surname><given-names>MA</given-names></name><name><surname>Gewitz</surname><given-names>MH</given-names></name><name><surname>Tani</surname><given-names>LY</given-names></name><name><surname>Burns</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>2747</fpage><lpage>2771</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000145143.19711.78</pub-id><?supplied-pmid 15505111?><pub-id pub-id-type="pmid">15505111</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durongpisitkul</surname><given-names>K</given-names></name><name><surname>Gururaj</surname><given-names>VJ</given-names></name><name><surname>Park</surname><given-names>JM</given-names></name><name><surname>Martin</surname><given-names>CF</given-names></name></person-group><article-title>The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment</article-title><source>Pediatrics</source><year>1995</year><volume>96</volume><fpage>1057</fpage><lpage>1061</lpage><?supplied-pmid 7491221?><pub-id pub-id-type="pmid">7491221</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terai</surname><given-names>M</given-names></name><name><surname>Shulman</surname><given-names>ST</given-names></name></person-group><article-title>Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose</article-title><source>J Pediatr</source><year>1997</year><volume>131</volume><fpage>888</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(97)70038-6</pub-id><?supplied-pmid 9427895?><pub-id pub-id-type="pmid">9427895</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>McCrindle</surname><given-names>BW</given-names></name><name><surname>Minich</surname><given-names>LL</given-names></name><name><surname>Gersony</surname><given-names>W</given-names></name><name><surname>Vetter</surname><given-names>VL</given-names></name><etal/></person-group><article-title>Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>663</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa061235</pub-id><?supplied-pmid 17301297?><pub-id pub-id-type="pmid">17301297</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Saji</surname><given-names>T</given-names></name><name><surname>Otani</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>1613</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)61930-2</pub-id><?supplied-pmid 22405251?><pub-id pub-id-type="pmid">22405251</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Krucoff</surname><given-names>MW</given-names></name></person-group><article-title>Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis</article-title><source>Heart</source><year>2013</year><volume>99</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2012-302126</pub-id><?supplied-pmid 22869678?><pub-id pub-id-type="pmid">22869678</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>JC</given-names></name><name><surname>Mason</surname><given-names>WH</given-names></name><name><surname>Hauger</surname><given-names>SB</given-names></name><name><surname>Janai</surname><given-names>H</given-names></name><name><surname>Bastian</surname><given-names>JF</given-names></name><name><surname>Wohrley</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Infliximab treatment for refractory Kawasaki syndrome</article-title><source>J Pediatr</source><year>2005</year><volume>146</volume><fpage>662</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2004.12.022</pub-id><?supplied-pmid 15870671?><pub-id pub-id-type="pmid">15870671</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brogan</surname><given-names>RJ</given-names></name><name><surname>Eleftheriou</surname><given-names>D</given-names></name><name><surname>Gnanapragasam</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>NJ</given-names></name><name><surname>Brogan</surname><given-names>PA</given-names></name></person-group><article-title>Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report</article-title><source>Pediatr Rheumatol</source><year>2009</year><volume>7</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/1546-0096-7-3</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillevin</surname><given-names>L</given-names></name><name><surname>Lhote</surname><given-names>F</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Jarrousse</surname><given-names>B</given-names></name><name><surname>Lortholary</surname><given-names>O</given-names></name><name><surname>Genereau</surname><given-names>T</given-names></name><etal/></person-group><article-title>Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients</article-title><source>Arthritis Rheum</source><year>1995</year><volume>38</volume><fpage>1638</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1002/art.1780381116</pub-id><?supplied-pmid 7488285?><pub-id pub-id-type="pmid">7488285</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribi</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Pagnoux</surname><given-names>C</given-names></name><name><surname>Mahr</surname><given-names>A</given-names></name><name><surname>Arene</surname><given-names>JP</given-names></name><name><surname>Puechal</surname><given-names>X</given-names></name><etal/></person-group><article-title>Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients</article-title><source>Arthritis Rheum</source><year>2010</year><volume>62</volume><fpage>1186</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1002/art.27340</pub-id><?supplied-pmid 20131268?><pub-id pub-id-type="pmid">20131268</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gayraud</surname><given-names>M</given-names></name><name><surname>Guillevin</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Lhote</surname><given-names>F</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name><name><surname>Deblois</surname><given-names>P</given-names></name><etal/></person-group><article-title>Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides</article-title><source>Br J Rheumatol</source><year>1997</year><volume>36</volume><fpage>1290</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/36.12.1290</pub-id><?supplied-pmid 9448590?><pub-id pub-id-type="pmid">9448590</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillevin</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Mahr</surname><given-names>A</given-names></name><name><surname>Arene</surname><given-names>JP</given-names></name><name><surname>Mouthon</surname><given-names>L</given-names></name><name><surname>Puechal</surname><given-names>X</given-names></name><etal/></person-group><article-title>Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients</article-title><source>Arthritis Rheum</source><year>2003</year><volume>49</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1002/art.10922</pub-id><?supplied-pmid 12579599?><pub-id pub-id-type="pmid">12579599</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampson</surname><given-names>L</given-names></name><name><surname>Whitehead</surname><given-names>J</given-names></name><name><surname>Eleftheriou</surname><given-names>D</given-names></name><name><surname>Tudur-Smith</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Jayne</surname><given-names>D</given-names></name><etal/></person-group><article-title>Elicitation of expert prior opinion: application to the mypan trial in childhood polyarteritis nodosa</article-title><source>Pediatric Rheumatology</source><year>2014</year><volume>12</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1546-0096-12-S1-P125</pub-id><pub-id pub-id-type="pmid">24393408</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>R</given-names></name><name><surname>Al-Taiar</surname><given-names>A</given-names></name><name><surname>Mooney</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>MacGregor</surname><given-names>A</given-names></name></person-group><article-title>The epidemiology of Takayasu arteritis in the UK</article-title><source>Rheumatology</source><year>2009</year><volume>48</volume><fpage>1008</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kep153</pub-id><?supplied-pmid 19542212?><pub-id pub-id-type="pmid">19542212</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Bali</surname><given-names>HK</given-names></name><name><surname>Kumar</surname><given-names>L</given-names></name><name><surname>Sharma</surname><given-names>BK</given-names></name></person-group><article-title>Takayasu arteritis in children and young indians</article-title><source>Int J Cardiol</source><year>2000</year><volume>75</volume><issue>Suppl 1</issue><fpage>S153</fpage><lpage>S157</lpage><pub-id pub-id-type="doi">10.1016/S0167-5273(00)00180-7</pub-id><?supplied-pmid 10980355?><pub-id pub-id-type="pmid">10980355</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>E</given-names></name><name><surname>Pineda</surname><given-names>C</given-names></name><name><surname>Martinez-Lavin</surname><given-names>M</given-names></name></person-group><article-title>Takayasu&#8217;s arteritis in children</article-title><source>J Rheumatol</source><year>1991</year><volume>18</volume><fpage>1081</fpage><lpage>1084</lpage><?supplied-pmid 1681102?><pub-id pub-id-type="pmid">1681102</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>J</given-names></name><name><surname>Feldman</surname><given-names>BM</given-names></name><name><surname>Tyrrell</surname><given-names>PN</given-names></name><name><surname>Kuemmerle-Deschner</surname><given-names>JB</given-names></name><name><surname>Zimmerhackl</surname><given-names>LB</given-names></name><name><surname>Gassner</surname><given-names>I</given-names></name><etal/></person-group><article-title>Takayasu arteritis in children and adolescents</article-title><source>Rheum (Oxford)</source><year>2010</year><volume>49</volume><fpage>1806</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keq167</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Tomomasa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>2606</fpage><lpage>2612</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.592865</pub-id><?supplied-pmid 16735679?><pub-id pub-id-type="pmid">16735679</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozen</surname><given-names>S</given-names></name><name><surname>Duzova</surname><given-names>A</given-names></name><name><surname>Bakkaloglu</surname><given-names>A</given-names></name><name><surname>Bilginer</surname><given-names>Y</given-names></name><name><surname>Cil</surname><given-names>BE</given-names></name><name><surname>Demircin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Takayasu Arteritis in Children: Preliminary Experience with Cyclophosphamide Induction and Corticosteroids Followed by Methotrexate</article-title><source>J Pediatr</source><year>2007</year><volume>150</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2006.10.059</pub-id><?supplied-pmid 17188618?><pub-id pub-id-type="pmid">17188618</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>F</given-names></name><name><surname>Kawakami</surname><given-names>A</given-names></name><name><surname>Iwanaga</surname><given-names>N</given-names></name><name><surname>Tamai</surname><given-names>M</given-names></name><name><surname>Izumi</surname><given-names>Y</given-names></name><name><surname>Aratake</surname><given-names>K</given-names></name><etal/></person-group><article-title>Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate</article-title><source>Intern Med</source><year>2006</year><volume>45</volume><fpage>313</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.45.1377</pub-id><?supplied-pmid 16596001?><pub-id pub-id-type="pmid">16596001</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakaoka</surname><given-names>Y</given-names></name><name><surname>Higuchi</surname><given-names>K</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Otsuki</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Hashimoto-Kataoka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Tocilizumab for the treatment of patients with refractory takayasu arteritis</article-title><source>Internat Heart Jour</source><year>2013</year><volume>54</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1536/ihj.54.405</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancheo</surname><given-names>BB</given-names></name><name><surname>Perin</surname><given-names>F</given-names></name><name><surname>Guez Vazquez Del Rey Mdel</surname><given-names>M</given-names></name><name><surname>Ga</surname><given-names>SA</given-names></name><name><surname>Romero</surname><given-names>PPA</given-names></name></person-group><article-title>Successful tocilizumab treatment in a child with refractory Takayasu arteritis</article-title><source>Pediatrics</source><year>2012</year><volume>130</volume><fpage>e1720</fpage><lpage>e1724</lpage><pub-id pub-id-type="doi">10.1542/peds.2012-1384</pub-id><pub-id pub-id-type="pmid">23147976</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Ombrello</surname><given-names>AK</given-names></name><name><surname>Zavialov</surname><given-names>AV</given-names></name><name><surname>Toro</surname><given-names>C</given-names></name><name><surname>Zavialov</surname><given-names>AV</given-names></name><etal/></person-group><article-title>Early-onset stroke and vasculopathy associated with mutations in ADA2</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>911</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1307361</pub-id><?supplied-pmid 24552284?><pub-id pub-id-type="pmid">24552284</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navon Elkan</surname><given-names>P</given-names></name><name><surname>Pierce</surname><given-names>SB</given-names></name><name><surname>Segel</surname><given-names>R</given-names></name><name><surname>Walsh</surname><given-names>T</given-names></name><name><surname>Barash</surname><given-names>J</given-names></name><name><surname>Padeh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>921</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1307362</pub-id><?supplied-pmid 24552285?><pub-id pub-id-type="pmid">24552285</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jesus</surname><given-names>AA</given-names></name><name><surname>Marrero</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Ramsey</surname><given-names>SE</given-names></name><name><surname>Montealegre Sanchez</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Activated STING in a vascular and pulmonary syndrome</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>507</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1312625</pub-id><?supplied-pmid 25029335?><pub-id pub-id-type="pmid">25029335</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ramot</surname><given-names>Y</given-names></name><name><surname>Torrelo</surname><given-names>A</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Si</surname><given-names>N</given-names></name><name><surname>Babay</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mutations in PSMB8 cause CANDLE syndrome with evidence of genetic and phenotypic heterogeneity</article-title><source>Arthritis Rheum</source><year>2012</year><volume>64</volume><fpage>895</fpage><pub-id pub-id-type="doi">10.1002/art.33368</pub-id><?supplied-pmid 21953331?><pub-id pub-id-type="pmid">21953331</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batu</surname><given-names>ED</given-names></name><name><surname>Karadag</surname><given-names>O</given-names></name><name><surname>Taskiran</surname><given-names>EZ</given-names></name><name><surname>Kalyoncu</surname><given-names>U</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Alikasifoglu</surname><given-names>M</given-names></name><etal/></person-group><article-title>A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations</article-title><source>J Rheumatol</source><year>2015</year><volume>42</volume><fpage>1532</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.3899/jrheum.150024</pub-id><?supplied-pmid 26233953?><pub-id pub-id-type="pmid">26233953</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing, A, Berg S, Ekelund M, Jolles S, Harper L, Youngstein T, Gilmour K, Klein N, Eleftheriou D, Brogan PA. Deficiency of adenosine deaminase type 2 (DADA2): a description of phenotype and genotype in 15 cases. Arthritis and Rheumatism, In press.</mixed-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Montfrans MD</surname><given-names>J</given-names></name><name><surname>Zavialov</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Ombrello</surname><given-names>AK</given-names></name></person-group><article-title>Mutant ADA2 in vasculopathies</article-title><source>N Engl J Med</source><year>2014</year><volume>2014</volume><fpage>478</fpage><lpage>481</lpage></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brehm</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Marrero</surname><given-names>B</given-names></name><name><surname>Omoyinmi</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production</article-title><source>J Clin Invest</source><year>2015</year><volume>125</volume><fpage>4196</fpage><lpage>4211</lpage><pub-id pub-id-type="doi">10.1172/JCI81260</pub-id><?supplied-pmid 26524591?><pub-id pub-id-type="pmid">26524591</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omoyinmi</surname><given-names>E</given-names></name><name><surname>Melo Gomes</surname><given-names>S</given-names></name><name><surname>Nanthapisal</surname><given-names>S</given-names></name><name><surname>Woo</surname><given-names>P</given-names></name><name><surname>Standing</surname><given-names>A</given-names></name><name><surname>Eleftheriou</surname><given-names>D</given-names></name><etal/></person-group><article-title>Stimulator of Interferon Genes&#915;&#199;&#244;Associated Vasculitis of Infancy</article-title><source>Arthritis &amp; Rheumatology</source><year>2015</year><volume>67</volume><fpage>808</fpage><pub-id pub-id-type="doi">10.1002/art.38998</pub-id><pub-id pub-id-type="pmid">25510345</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crow</surname><given-names>YJ</given-names></name></person-group><article-title>Type I interferonopathies: a novel set of inborn errors of immunity</article-title><source>Ann NY Acad Sci s</source><year>2011</year><volume>1238</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2011.06220.x</pub-id></element-citation></ref></ref-list></back></article>